Top
Main

All outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Bamlanivimab/etesevimab  COVID-19 treatment studies for Bamlaniv../e..  C19 studies: Bamlaniv../e..  Bamlaniv../e..   Select treatmentSelect treatmentTreatmentsTreatments
Antiandrogens (meta) Lactoferrin (meta)
Aspirin (meta) Melatonin (meta)
Bamlaniv../e.. (meta) Metformin (meta)
Bebtelovimab (meta) Molnupiravir (meta)
Bromhexine (meta) N-acetylcys.. (meta)
Budesonide (meta) Nigella Sativa (meta)
Cannabidiol (meta) Nitazoxanide (meta)
Casirivimab/i.. (meta) Paxlovid (meta)
Colchicine (meta) Peg.. Lambda (meta)
Conv. Plasma (meta) Povidone-Iod.. (meta)
Curcumin (meta) Probiotics (meta)
Diet (meta) Proxalutamide (meta)
Ensitrelvir (meta) Quercetin (meta)
Ensovibep (meta) Remdesivir (meta)
Exercise (meta) Sleep (meta)
Famotidine (meta) Sotrovimab (meta)
Favipiravir (meta) Tixagev../c.. (meta)
Fluvoxamine (meta) Vitamin A (meta)
Hydroxychlor.. (meta) Vitamin C (meta)
Iota-carragee.. (meta) Vitamin D (meta)
Ivermectin (meta) Zinc (meta)

Other Treatments Global Adoption
Loading...
Antiandrogens
Aspirin
Bromhexine
Budesonide
Cannabidiol
Casirivimab/i..
Colchicine
Conv. Plasma
Curcumin
Diet
Ensovibep
Exercise
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Melatonin
Metformin
Molnupiravir
Nigella Sativa
Nitazoxanide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Proxalutamide
Quercetin
Remdesivir
Sleep
Sotrovimab
Vitamin A
Vitamin C
Vitamin D
Zinc
Supplementary Data — Bamlanivimab/etesevimab for COVID-19: real-time meta analysis of 14 studies
Covid Analysis, June 28, 2022, DRAFT
https://c19ly.com/meta.html
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Gottlieb (RCT) 71% 0.29 [0.09-0.96] hosp./ER 4/101 7/52 Improvement, RR [CI] Treatment Control Gottlieb (RCT) 80% 0.20 [0.03-1.56] hosp./ER 1/37 7/52 Gottlieb (RCT) 75% 0.25 [0.03-1.92] hosp./ER 1/30 7/52 Gottlieb (RCT) 56% 0.44 [0.10-1.98] hosp./ER 2/34 7/52 Gottlieb (RCT) 92% 0.08 [0.00-1.39] hosp./ER 0/31 7/52 Webb 80% 0.20 [0.03-1.46] death 1/479 57/5,536 Webb 53% 0.47 [0.31-0.72] hosp. 22/479 538/5,536 Webb 27% 0.73 [0.65-0.82] hosp./ER 65/479 1,018/5,536 Dougan (DB RCT) 95% 0.05 [0.00-0.90] death 0/518 9/517 Dougan (DB RCT) 70% 0.30 [0.16-0.59] death/hosp. 11/518 36/517 Dougan (DB RCT) 11% 0.89 [0.82-0.97] recov. time 518 (n) 517 (n) Dougan (DB RCT) 67% 0.33 [0.25-0.45] viral+ 50/508 147/499 Cooper 45% 0.55 [0.07-3.99] death 1/473 33/8,534 Cooper 58% 0.42 [0.10-1.72] ICU 2/473 85/8,534 Cooper 5% 0.95 [0.69-1.30] hosp. 37/473 703/8,534 Cooper -17% 1.17 [0.59-2.32] death 11/2,427 33/8,534 Cooper 9% 0.91 [0.57-1.45] ICU 22/2,427 85/8,534 Cooper 28% 0.72 [0.61-0.86] hosp. 144/2,427 703/8,534 Rubin 44% 0.56 [0.07-4.33] death 1/191 10/1,066 Rubin 65% 0.35 [0.12-0.94] hosp. 16/191 121/1,065 Delasobera -119% 2.19 [0.23-20.9] death 3/253 1/185 Delasobera 52% 0.48 [0.27-0.85] hosp. 17/253 26/185 Delasobera 20% 0.80 [0.46-1.40] progression 23/253 21/185 Dale 89% 0.11 [0.02-0.55] death 5/56 9/19 Dale 86% 0.14 [0.04-0.52] progression 6/56 10/19 Dale 54% 0.46 [0.08-1.97] progression 6/56 3/19 Wilden 51% 0.49 [0.23-1.04] hosp. n/a n/a ACTIV-3/T.. (RCT) -100% 2.00 [0.69-5.83] death 9/163 5/151 Bariola 67% 0.33 [0.10-1.01] death 4/234 12/234 Bariola 64% 0.36 [0.20-0.61] death/hosp. 16/234 45/234 Bariola 61% 0.39 [0.22-0.70] hosp. 15/234 39/234 Ganesh 74% 0.26 [0.05-1.20] death 2/1,789 8/1,832 Ganesh 49% 0.51 [0.24-1.09] ICU 10/1,789 20/1,832 Ganesh 37% 0.63 [0.43-0.91] hosp. 44/1,789 72/1,832 Chew (RCT) 25% 0.75 [0.26-2.10] hosp. 6/159 8/158 Chew (RCT) 52% 0.48 [0.09-2.49] hosp. 2/48 4/46 Chew (RCT) -1% 1.01 [0.26-3.93] hosp. 4/111 4/112 Chew (RCT) -14% 1.14 [0.00-455] recov. time 48 (n) 46 (n) Chew (RCT) -17% 1.17 [0.98-1.40] recov. time 111 (n) 112 (n) Chew (RCT) 26% 0.74 [0.62-0.90] viral load 48 (n) 46 (n) Chew (RCT) 35% 0.65 [0.40-1.04] viral load 111 (n) 112 (n) Priest (PSM) 0% 1.00 [0.33-3.07] death 6/379 6/379 Priest (PSM) -4% 1.04 [0.78-1.38] hosp. 79/379 76/379 Priest (PSM) -5% 1.05 [0.73-1.52] hosp./ER 379 (n) 379 (n) Lilly (RCT) 57% 0.43 [0.28-0.67] symp. case 483 (n) 482 (n) Lilly (RCT) 80% 0.20 [0.08-0.47] symp. case 150 (n) 149 (n) bamlanivimab/etesevimab COVID-19 outcomes c19ly.com Jun 2022 Favors bamlanivimab/e.. Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are both valuable and complementary. All practical, effective, and safe means should be used. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. Denying the efficacy of any method increases mortality, morbidity, collateral damage, and the risk of endemic status. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit